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Summary
Human immunodeficiency virus (HIV) binds to cells via an interaction between CD4 and the
virus envelope glycoprotein, gp120. Previous studies have localized the high affinity binding site
for gp120 to the first domain of CD4, and monoclonal antibodies (mAbs) reactive with this
region compete with gp120 binding and thereby block virus infectivity and synrytium formation.
Despite a detailed understanding of the binding of gp120 to CD4, little is known of subsequent
events leading to membrane fusion and virus entry. We describe two new mAbs reactive with
the third domain ofCD4 that inhibit steps subsequentto virus binding critical for HIV infectivity
and cell fusion. Binding of recombinant gp120 or virus to CD4 is not inhibited by these antibodies,
whereas infection and synrytium formation by a number of HIV isolates are blocked. These
findings demonstrate that in addition to virus binding, CD4 may have an active role in membrane
fusion.
C
D4 is the high affinity cellular receptor for HIV and
is found predominantly on thymus-derived T lympho-
cytes (1) . The structure predicted for CD4 is an extracellular
region of four tandem domains having homology with mem-
bers of the Ig superfamily, followed by a transmembrane do-
main and a cytoplasmic region (2, 3) . HIV binds CD4 via
the major envelope glycoprotein, gp120, and recent genetic
studies have localized the high affinity gp120 binding site on
CD4 to -12 amino acids within the NH2-terminal, Ig-like
(V1) domain (4-6). Similarly, residues have been defined in
the COOH-terminal half of gp120 that are critical for CD4
binding (7, 8). It is clear that the interaction between CD4+
human cells and cells expressing HIV envelope is sufficient
to induce synrytium formation (9-11), and that virus entry
is by pH-independent fusion ofthe virus and cell membranes
(12, 13). Little else is known, however, about the events sub-
sequent to binding that lead to membrane fusion.
Recently, evidence from two studies suggests that CD4
may play a role in cell-cell fusion (synrytium formation) ad-
ditional to envelope binding. In the first study, single residue
substitutions made in the CDR-3 analogous loop of the V1
domain of CD4 resulted in mutant molecules that were un-
able to facilitate synrytium formation, even though they medi-
ated both virus binding and infectivity to an extent com-
parable with wild-type CD4 (14). In the second, chemical
mutagenesis of a CD4+ T cell line resulted in CD4 mole-
cules that bound gp120 but mediated synrytium formation
poorly (15). Although the mechanism of inhibition of cell
fusion was not elucidated in either study, the findings indi-
cate that CD4 participates in events subsequent to gp120
binding that are required for membrane fusion. mAbs reac-
tive with CD4/V1 are highly efficient at inhibiting the binding
of gp120 to CD4, and therebyprevent infection and synrytium
formation (6, 16-19). In contrast, a mAb reactive with the
third or fourth CD4 domains has been shown not to inhibit
gp120 binding (18, 19) . To investigate whether regions of
CD4 other than the gp120 binding site are important in virus
infection, we have raised and characterized a panel of CD4
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inhibiting HIV/CD4 binding, andyet potently inhibit both
HIV infection and syncytium formation in vitro.
Materials and Methods
CD4 mAbs
ApanelofCD4mAbs wasprepared by immunization ofBALB/c
mice with four intraperitonealinoculations at 3-wk intervals with
the CD4-transfected mouseT cell hybridoma 3DT (20), followed
by a similar schedule with the CD4+ human T cell line CEM.
Mousesplenocytes were fusedwith theNS-1 myelomaby standard
procedures (21), and hybridoma supernatants were screened for:
(a) binding to recombinant soluble CD4 (sCD4;t from R. Sweet,
SmithKline BeechamLaboratories,King of Prussia, PA.; 22)in an
ELISA; (b) reactivity with CD4+-transfected mouse cells and
humanPBLby indirect immunofluorescence and flow cytometry;
(c)inhibition of HIVinducedsyncytiumformation in a cocultiva-
tion assay (16); and(d) ability to block purified, recombinant gp120
(prepared in CHO cells by Celltech Ltd., Slough, UK., for the
MedicalResearch CouncilAIDS-Directed Programme) bindingto
CD4. Two hybridomas were selected (Q425 and Q428) that pro-
duced Ig reactive with CD4 in all of the above assays, and that
inhibited syncytium formation, but did not block gp120binding
to CD4. After cloning, purified Ig was used to repeat the above
assays and to determine the ability of these mAbs to inhibit HIV
infection of CD4+ T cells. Other mAbs used were from the fol-
lowing sources: OKT4, (P. Rao; Ortho Diagnostic Systems Inc.,
Westwood, MA); MT429 and MT151 (P. Reiber and G. Reith-
muller; Munich University, Munich, FRG); and anti-Leu-3a, (from
here on referred to as Leu-3a; N. Warner; Becton Dickinson Mono-
clonal Center Inc., SanJose, CA). L120 andQ4120 were prepared
by D. Buck and Q. Sattentau respectively.
CD4 mAb Crosscompetition Studies
CD4 mAbs were labeled with biotin by the following proce-
dure. To mAbat aconcentrationof 100 FAg/ml previously dialyzed
against 0.1 M bicarbonate buffer (pH 8.4) was added 50 pl of 1
mg/mlbiotin-NHS (PierceChemical Co., Rockford, IL)in DMSO.
After overnight incubation at 4°C, excess biotin was removedby
dialysis against PBS'A'. Cells were incubatedwith 50 Al ofvarious
concentrations ofunlabeledCD4mAbranging from supersaturating
(20 ,ug/ml) to subsaturating (20 ng/ml), an irrelevant mAb, or
medium alone for30 min. 50 pl of200ng/mlofbiotinylated CD4
mAb was then added. After 45 min, the cells were washed and
50 td ofa 1/20,000 dilution ofstreptavidin peroxidase (K377;Dako
Corp., Santa Barbara, CA) was added. After a further 45-min in-
cubation, the cells were washed and the reaction developed in
o-phenylenediamine in citrate buffer (pH5). The cells were pelleted
and the absorbance of the supernatants was measured at 492 nm
after transfer to a separate, flat-bottomed plate.Allincubations were
carried out at 4°C. Percentage inhibition of labeled mAb binding
was calculated by the formula: 100x [(MT)/(M-C)], whereM
represents maximum absorbance in theabsenceofinhibitory mAb,
Tis absorbance in the presence of test mAb, and C is absorbance
in the presence of saturating concentrations of the homologous,
unlabeled mAb.
'Abbreviations used in this paper: RT, reverse transcriptase; sCD4, soluble
CD4.
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gp120 and mAb Binding Assays
Cell ELISAfor Inhibition ofgp120 Binding.
￿
HPB-ALL cells at
aconcentration of 5 x 104/ml in 100 Ad/well were incubatedwith
dilutions of CD4mAbs or medium alonein 96-wellround-bottomed
microtiter plates for 30 min, then the appropriate concentration
of recombinant gp120 wasadded. After a further 30-min incuba-
tion andwashing, 50,ulof 1pg/mlbiotin-labeled gp120mAb(9284;
DuPont Co., Wilmington, DE) (23) wasadded. Subsequent steps
were done as for mAb crosscompetition studies.
Cell ELISA forInhibition ofCD4mAbBinding by gp120.
￿
HPB-
ALLcells at 5 x 10°/ml in 100 14/well were incubated for 2 h
with 10 t~g/ml of gp120, a concentrationpreviously shownto su-
persaturate all CD4 molecules. CD4 mAbs at various concentra-
tionswere then added for another 1 h, and the cells were washed
and labeled with FITC-conjugated rabbit anti-mouse Ig (Sigma
Chemical Co., St. Louis, MO)for30 min. Afterfurther washing,
the cells were analyzed by flow cytometry on a FACscan (Becton
Dickinson & Co., Mountain View, CA).
Soluble CD4ELISA.
￿
Thebinding ofgp120to sCD4 captured
onto the solid phase by different CD4 mAbs was carried out as
follows. 100pl of 25 ttg/ml of purified CD4 mAb in bicarbonate
buffer (pH 8.5) was added to each well of a 96-well ELISA plate
overnight. After washing, nonspecific binding was blocked by a
30-min incubation with TBS containing 2% Marvel. After fur-
ther washing, sCD4 at 1 tag/ml wasadded. Thebindingofrecom-
binant gp120 was then detected as previously described (24).
HIV Binding Assay
The binding of a concentrated preparation of HIV-1 to CEM
cellsin thepresence or absence of CD4 mAbs was detected by in-
direct immunofluorescence and cytofluorometry as previously de-
scribed (25).
Mapping of mAb Binding Regions
Polypeptide Inhibition ofmAbBinding.
￿
Inhibition studiesofCD4
mAbbindingwere done by previouslydescribedprotocols(26) with
sCD4 and two truncated forms of this molecule: arecombinant,
solubleconstructconsisting ofthefirst twodomainsof CD4(amino
acids 1-183; from R. Sweet, SmithKline Beecham Laboratories;
6) andaproteolytic cleavage fragment ofsCD4 consisting ofresidues
178-369, which wasprepared as follows. Insolublea-chymotrypsin
coupled to agarose (Sigma Chemical Co.) was incubated with 5.6
MM tosyl-L-lysine chloromethyl ketone (TICK) for i h at 26°C
in 10 mM CaC12, 100mM Tris, pH 8.0. After thorough washing,
the TICKtreated chymotrypsin (5.0 U/ml) was incubated with
1.5 mg/ml sCD4 with constant mixing for 3.5 h at 27°C in 0.15
Msodium chloride, 50 MM DL-methionine, 50 mM Hepes, 30 mM
phosphate, pH 7.9. Thereaction mixturewascentrifuged to remove
chymotrypsin and the supernatant applied to aCon A-Sepharose
column (Pharmacia Fine Chemicals, Piscataway, NJ). The column
was washed, and bound protein was eluted with 0.5 M methyl
(X-D-mannopyranoside (Sigma Chemical Co.) . The 0.5-M fraction
was subjectedto gelfiltration on a Sephacryl 100HR column (Phar-
macia Fine Chemicals) in 150 mM NaCl, 50 mM sodium phos-
phate, 20 mM sodium cacodylate, pH 7.25, 0.01 mM PMSF. The
largestpeak waspooled andpassed down acolumn ofLeu-3a bound
to anti-mouse IgG covalently linked to sepharose beads (Sigma
Chemical Co.) to remove any residual reactive material. Thepeak
migrated as ahomogeneoussingleband at 30.5 kD on SDS-PAGE.
NH2-terminal sequence analysis gave a single sequence (AFQKAS-
IVY) forthefirst 10 cycles, whichcorresponds to residues 178-187
of therecombinant CD4. Results from amino acid compositional
CD4 Antibodies Block Infection of Human Immunodeficiency Virusanalysis were consistent with a CD4 peptide of 178-369 with a
calculated molecular mass of 24.5 kD (assuming twobiantennary
carbohydrate attachments; 27). Limiting concentrations of theCD4
mAbs were incubated for 30 min with various concentrations of
the inhibitory polypeptides, then added to SUPTI cells. Bound
mAbwas detected with a fluoresceinated anti-mouse Ig antibody.
Percentage inhibition of binding was calculated by the formula:
100x [(MFc-MFt)/(MFc-MFs)J, whereMFis the mean channel
fluorescence without CD4protein (c), with truncated test peptide
(t), and withoutCD4mAb(s). Allincubations were done at 4°C.
mAb Reactivity with Recombinant Human/Mouse CD4.
￿
Mole-
cules of CD4chimeric between human and mouse have been pre-
pared by homologous recombination in bacteria as previously de-
scribed (28). Cell surfaceexpression aftertransfection ofthecDNA
was detected on mouse EL,4 cells by indirect immunofluorescent
staining with the CD4mAbs, and analyzed by flow cytometryon
a FACscan (Becton Dickinson & Co.).
Culture of HIVinfected and -uninfected Cell Lines
H9 cellspersistently infected with HIV-1 isolates HTLVIIIB and
HTLVIIIRF(obtainedfrom R. Gallo, National Institutes ofHealth,
Bethesda, MD) and CBL4 (P. Clapham andR. A. Weiss, Chester-
Beatty Laboratories, London, UK) or HIV-2 isolates LAV2 ROD
(L. Montagnier, Pasteur Institute, Paris, France) and CBL20 (P.
Clapham), and uninfected lines SUPT1 (J. Hoxie, University of
Pbmnsylvania, Philadelphia, PA), C8166 (R. Gallo), CEM, andHPB-
ALLwere cultured in RPMI 1640 (Gibco Laboratories, Grand Is-
land, NY) supplemented with 10% heat-inactivated FCS. TheCD4-
transfected cell lines Hela (Hela T4, from R. Axel, Columbia
University, NewYork, NY) and3DT(20) were grownin DMEM
with 10% FCS and 1 mg/ml G418 (Geneticin; Sigma Chemical
Co.) or RPMI 1640 + 10% FCS and 500 hg/ml G418, respec-
tively. HIVcontaining supernatants were harvested from 5-d cul-
tures of a 4:1 mixture of uninfected H9 cells with HIV-infected
H9, and titrated on C8166 cells by syncytium assay to determine
the TCIDso.
Assays ofHIV Syncytium Formation and Infectivity
Syncytiumassays were done as previously described(16) by over-
nightcocultivationofHIV-infected H9 cellswith uninfected C8166
cells at aratioof 1:2, in thepresence or absenceof inhibitory anti-
body. Infection of C8166 cells was determined after addition of
-1,000 TCIDso of virus in three assays: (a) measurement of syn-
CD4 mAbs at subsaturating concentrations (10-100 ng/ml) were incubated with a molar excess (80 nM) of sCD4-derived polypeptide, then added
to 5 x 104 HPB-ALL cells. After washing, bound mAb was detected by immunofluorescent staining and flow cytometry.
Amino acid allocations in polypeptide.
t Percent inhibition of mAb binding to CD4' cells.
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cytium formation; (b) measurement of reverse transcriptase (RT)
activity in culture supernatants. This was carried out by the fol-
lowing procedure. 80 Al of a cocktail of 50 mM Tris, pH 8.0, 5
rnMDTT, 5 mM KDI, 0.05% Triton X-100, 0.3 mM glutathione,
0.5 mM EGTA, and 50 Ag/ml template primer [poly(rA)p.(dT)j
was addedinto each well of a round-bottomed 96-well plate. Test
supernatant or medium (20IA1) was added, and the plate was in-
cubated on ice for 10 min. Me['H]Thymidine 5' triphosphate (20
,al of 0.1 mCi/ml) was added to each well, and the plates were
incubated at 37°C for 2 h. The plates were then harvested onto
a DE81 filter mat, washed in 2x SSC and 95% ethanol, dried,
and counted in a ft platescintillation counter (LKB Instruments,
Inc., Gaithersburg, MD). (c)Measurementofsoluble p24HIVcore
antigen by twin site ELISA. Supernatants were inactivated by
heating for 30 min at 56°C in 1% Empigen detergent, diluted
100-1,000-fold into TBS/0.1% Empigen, and 100 ttl was added
to 96-well microtiter plates containing adsorbed sheep anti-p24 pep-
tide polyclonal antibody, D7320 (Aalto BioReagen% Ireland). Cap-
turedp24wasdetected with alkaline phosphatase-conjugated mAb
EH12EI (29; obtained throughtheMedicalResearch CouncilAIDS-
Directed Programme). The assaywascalibrated usingpurified p24
yeast TyVLPprotein(30;prepared by British BioTechnology Ltd.,
Oxford, UK; a gift from S. Adams).
Results
Mapping ofQ42S and Q428 Epitopes.
￿
To localize broadly
the epitopes of the CD4 mAbs, binding inhibition studies
were done with threeformsof CD4: whole sCD4, a recom-
binant polypeptide consisting of the first 183 amino acids,
and a proteolytically cleaved fragment spanning residues
178-369. Table 1 shows that preincubation of allmAbs with
80 nM sCD4 abrogates binding to CD4+ cells. The same
molar concentration of the 1-183 peptide inhibited Leu-3a
and Q4120 binding, whereas an equivalent concentration of
the 178-369 peptide blocked all theothermAbs. Thus, Q425,
Q428, L120, MT429, andOKT4 bind in the thirdor fourth
domains. Leu-3a binds in the first two domains of CD4, in
accord with previous studies showing V1 reactivity (4, 6,
26), as does Q4120, whichwe have also shown to bind within
V1 (unpublished results). Furthercharacterization was achieved
by phenotypic analysis of cells expressing a panel of hu-
Table 1. Inhibition of CD4
Polypeptide
mAb Binding
Leu-3a
by CD4 Polypeptides
Q4120 Q425
Percent inhibition
Q428 OKT4 L120 MT429
Domains 1+2 (1-183)' 98t 96 5 4 6 3 5
Domains 3+4 (178-369) 0 2 95 85 67 93 91
sCD4 (1-369) 97 93 100 97 89 100 96CD4 mAbs at saturating concentration (10 14g/ml) were incubated with
EL-4 cells expressing molecules recombinant between human and mouse
CD4. mAb binding was detected by indirect immunofluorescence and
flow cytometry. (-) No reactivity (mean fluorescence intensity [MFI]
< 5 U abovebackground); (+) weak reactivity (MFI 6-15 U above back-
ground; ( + + ) strong reactivity (MFI > 16 U above background). Hu,
human; Mo, mouse.
man/mouse chimeric CD4 molecules with the CD4 mAbs.
Recombinant cDNA molecules were constructed by homol-
ogous recombination between human and mouse cDNA,
yielding molecules containing various amounts of NH2-
terminal murine sequencejoined to human sequence. Trans-
fection of the recombinant cDNA into murine EIr4 cells
resulted in cell surface expression of chimeric protein. Table
2 shows that Q425, Q428, and OKT4 require the first 292
residues for binding, and 1,120 probably binds in the 000H-
terminal 67 residues. In contrast, Leu-3a binds within the
first 79 amino acids. Taken together with the peptide inhibi-
tion data, these results demonstrate that Q425, Q428, and
OKT4 react with a stretch of amino acids bounded by
Table 3 . Crosscompetition between CD4 mAbs
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178-292, approximating to the third domain of CD4. Ex-
periments using a panel of cells expressing CD4 molecules
containing site-directed mutations showed that Q425 and
Q428 require conservation of residues 249-252 for binding
(R. Sekaly, personal communication). This finding supports
the localization of these mAbs in domain 3 of CD4. In a
previous study (26), OKT4 was unreactive with a CD4 mol-
ecule lacking the fourth domain, implying that this domain
may contain the OKT4 binding site. These data probably
reflect gross distortion ofCD4 structure in this region, how-
ever, since the current study suggests that OKT4 probably
binds in domain 3.
Crosscompetition studies between labeled and unlabeled
mAbs indicate the spatial proximity between epitopes on an
antigen (18, 26) . Q425 and Q428 show complete reciprocal
inhibition demonstrating closely related, overlapping, or iden-
tical epitopes (Table 3). Binding of these mAbs is partially
inhibited by OKT4 and 1,120, implying steric hindrance. The
epitope of MT429 is related to those of 1,120 and OKT4,
since binding of labeled MT429 is completely (1,120) or par-
tially (OKT4) blocked by these mAbs. As expected, the V1
mAbs Leu-3a and Q4120 did not interfere with Q425 or Q428
binding, nor was there any reciprocal interaction. Neither
Q425 nor Q428 binding is inhibited by MT151, a mAb reac-
tive with the first two domains of CD4 (4, 26) .
Effect o,fQ425 and Q428 on Binding ofgp120 and Virus.
￿
We
tested the effect of Q425 and Q428 on gp120 binding to
CD4+ cells. Neither of these mAbs inhibited gp120 binding
at any concentration tested; indeed, a small but reproducible
enhancement of gp120 reactivity was detected (Fig. 1) (31) .
It is unlikely that this effect is related to the inhibition of
HIV infection and cell fusion by Q425 and Q428, since other
mAbs that also increase gp120/CD4 binding to a similar ex-
tent (OKT4 and 1,120) are unable to inhibit in these assays.
Other mAbs showed a pattern of gp120 inhibition similar
to that observed in previous studies: both Leu-3a and Q4120
completely blocked gp120 binding at low concentrations,
Biotin-labeled CD4 mAbs (200 ng/ml) were incubated with 5 x 104 HPB-ALL cells in the presence or absence of an excess of unlabeled CD4
mAb. Bound labeled mAb was detected with avidin/horseradish peroxidase in an ELISA.
Percent inhibition of labeled mAb binding to CD4' cells.
CD4 Antibodies Block Infection of Human Immunodeficiency Virus
Percent inhibition
Q425 Q428 OKT4 1,120
0 0 0 0
0 0 0 0
0 0 0 0
100 100 50 50
100 100 50 100
0 0 55 100
20 20 65 100
Table 2 . Binding of CD4 mAbs to Mouse/Human Chimeras
Reactivity
Chimeric CD4 Leu-3a Q425 Q428 OKT4 1,120
Hu ++ + ++ ++ ++
Mo (22) Hu ++ ++ ++ ++ ++
Mo (79) Hu - + + + + + + + +
Mo (118) Hu - , ++ ++ ++ ++
Mo (292) Hu - - - - + +
Mo (305) Hu - - - - + +
Mo - - - - +
Biotin-labeled
CD4 mAb Leu-3a Q4120 MT151
Leu-3a 100' 100 0
Q4120 100 100 0
MT151 0 0 100
Q425 0 0 0
Q428 0 0 0
MT429 0 0 0
1,120 0 0 0CD4mAbconcentration (mg/ml)
whereas OKT4 and other mAbs binding to the 000H-
terminal portion of CD4 did not inhibit binding. We ex-
cluded the possibility thatQ425 and Q428 might appear not
to compete with gp120 binding because themAbs were dis-
placedby the high affinity interaction of gp120 with CD4,
by demonstrating the formation of a trimolecular complex
between sCD4, gp120, andQ425 or Q428. The binding of
gp120 to sCD4 captured onto the solidphase by variousCD4
mAbs was measured in an ELISA (Fig. 2) . The capture of
sCD4 by L120, Q425, and Q428 resulted in the binding of
similar quantities ofgp120, demonstrating that none ofthese
mAbs interfere with the gp120/CD4 interaction . Conversely,
capture ofsCD4 by Leu-3a orQ4120 prevented gp120 binding.
To investigate whether Q425 and Q428 were also unable to
inhibit binding ofwhole virions to CD4, we measured the
binding of a concentrated preparation of virus in the pres-
ence of thesemAbs (Fig. 3) . Neither of these mAbs nor L120
Figure 2 .
￿
Formation ofa trimolecular complex between sCD4, gp120,
and Q425 or Q428 . sCD4 was captured with CD4 mAbs preadsorbed
to an ELISA plate. The binding to the sCD4 of three concentrations of
gp120 was then measured by ELISA .
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Leu3a (1)
04120(1)
Q425 (3)
0428(3)
OKT4 (3)
MT429 (3,4)
L120(4)
Figure 1 .
￿
CD4 mAb inhibition ofgp120 binding
to CD4* cells. The binding of HIV gp120 (0.5
Wg/ml) to CD4' HPB-ALL cells was measured using
a biotinylated anti-gp120 mAb in the presence or ab-
sence ofprebound CD4mAbs. Numbersin parentheses
indicate the domain ofCD4 with which the CD4
mAbs react.
inhibited even at 100 hg/ml, whereas 04120 substantially
reduced virus binding at 10 Fig/ml .
Binding ofCD4 mAbs in the Presence of&120.
￿
The binding
of sub-saturating concentrations of CD4 mAbs to CD4+
cells was measured in the presence of pre-bound gp120 (Fig .
4). Surprisingly, Q425 and Q428 binding was substantially
reduced (by -50%) by increasing amounts ofgp120 in com-
parison with control reactivity. The reactivity ofothermAbs
binding to the COOH-terminal region of CD4 (OKT4,
MT429, and L120) was unaffected in the presence of gp120,
whereas the VI-reactivemAbs demonstrated a dose-dependent
reduction in binding with increasing gp120 concentration
as expected. Thus, although Q425 and Q428 do not inter-
fere with gp120 binding, in the reciprocal experiment, mAb
binding is substantially reduced. This effect is unique to gp120,
Figure 3 .
￿
Inhibition of HIV binding to CD4+ cells . The binding of
concentrated HIV to CD4+ CEM cells was detected by a FITC-labeled
anti-gp120 antiserum in the presence or absence ofCD4 mAbs. Results
are expressed as the test mean fluorescence indexes minus the background
control mean fluorescence. The dotted line indicates the binding of la-
beled virus in the absence of inhibitory mAb .c
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since pre-incubation with a panel of eight V1-reactive CD4
mAbs had no effect on Q425 or Q428 binding (data not
shown). To investigate whether the reduced binding ofQ425
and Q428 reflected a decrease in affinity for CD4 complexed
with gp120, the binding ofincreasing concentrations of these
mAbs was tested in the presence or absence of a saturating
concentration of prebound gp120 (Fig. 5). There was a clear
decrease of about fourfold in the affinity of Q425 and Q428
for CD4 complexed with gp120 as opposed to gp120 alone,
which may reflect an allosteric change induced in CD4 by
gp120 binding. Interestingly, there was also a small but
significant decrease in the saturation binding of these two
mAbs, implying a decrease in the number of binding sites
available.
Inhibition ofHIVinduced Syncytium Formation by Q425 and
0428. We tested the ability of Q425 and Q428 to block
syncytia induced by a variety of HIV-1 and HIV-2 isolates
(Table 4). Although there was some variation between virus
isolates, particularly with respect to strain RF with Q425,
500 ,
400 -I
200 -
a
Concentration ofgp120 (pglml)
0428+ gp120
100
01 1 1 10 100
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0425 (3)
0428 (3)
OKT4 (3)
MT429 (3,4)
L120 (4)
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both mAbs inhibited all isolates tested at concentrations within
N10-fold of those required to saturate 5 x 104 CD4+ cells.
Both Leu-3a and Q4120 inhibited all isolates at similar con-
centrations, and with similar potency to Q425 and Q428 rel-
ativeto theirsaturation binding. Previous studies have demon-
strated that OKT4 is unable to inhibit syncytium formation
(18, 19). Other mAbs binding to epitopes in the third or
fourth domains ofCD4 (MT429 and L120) also have no effect
on syncytium formation. To exclude the possibility that the
inhibition of syncytium formation by Q425 and Q428 was
the result of CD4 internalization, we incubated CD4+ cells
with Q425 and Q428 overnight at 37°C. No reduction in
the level of CD4 was detected (results not shown). Thus,
Q425 and Q428 show a previously undescribed inhibition
of HIV syncytium formation that is not related to down-
regulation of cell surface CD4, or interference with gp120
or whole virus binding.
Inhibition ofHIV Infection by Q425 and Q428.
￿
Since cell-cell
fusion induced in a short-term cocultivation assay of virus-
10 100
CD4 mAb concentration (jig/ml)
CD4 Antibodies Block Infection of Human Immunodeficiency Virus
Figure 4.
￿
Inhibition ofCD4 mAb binding by gp120.
The binding of biotin-labeled CD4 mAbs (0.2 jLg/ml)
to CD4+ HPB-ALL cells was measured in the presence
ofvarious concentrations ofpre-bound gp120. Results are
expressed as the percentage inhibition of mAb binding.
Figure 5.
￿
Binding of (a) Q428 and (b) Q425 to sCD4
complexed with gp120. The binding of Q425 or Q428
-M
￿
to CD4+ cells previously incubated with a saturating
concentration of gp120 was measured by indirect im-
munofluorescent staining and flow cytometry. Each point
represents the mean of three replicates. Error bars indi-
cate ±1 SD.C8166 cells (5 x 104) were mixed with HIV-infected H9 cells in thepresence of various concentrations of CD4mAbs. After overnightincubation,
the wells were scored for inhibition of syncytia.
" Domain of CD4 within which mAbs bind.
t Concentration of mAb required to saturate 5 x 104 HPB-ALL cells.
S Concentration of mAb required to inhibit syncytia by >80% .
infected and uninfected cells (fusion from without) may be
analogous to the mechanism of virus entry into receptor-
bearing cells, we investigated the effect of Q425 and Q428
on HIV infection. Table 5 shows the results of incubation
of the CD4+ T cell line C8166 with cell-free HIV (isolate
HTLVIIIB), in the presence or absence of CD4 mAb. By
threecriteria (syncytia, RT activity, and solublep24 antigen
release), Q425 and Q428 substantially reduced the titer of
HIV measured at various times after infection. Q425 was
more effectivethan Q428 at inhibiting HIVinfection, an ob-
servationthat mayimply that these mAbs recognize slightly
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differentepitopes. Adecrease in theinhibitory activity of Q428
and, to a lesser extent, Q425 was seen at days 4 and 5, prob-
ably reflecting breakthrough ofthe mAbinhibition by asmall
number of virus particles. Increasing the dose of these mAbs
to 20 /4g/ml eliminated this breakthrough (results not shown).
Complete inhibition of infection was achieved with the V1
mAb at all time points at 5 Ag/ml, implying that mAb
competition with HIVfor the binding site on CD4 maybe
amore efficient block to infection than that mediated by Q425
and Q428. The OKT4-like mAb MT429 was unable to in-
hibit HIV infection at any concentration tested.
absence of CD4 mAbs, and incubated for 3, 4, or C8166 cells were incubated with 1,000 syncytium-forming units of HIV in the presence or
5 d before assay.
CD4 domain within which mAb binds.
t Days after infection.
S Scoring for HIV-induced syncytia is as follows: (-) no syncytia; (+) <20% syncytia; (+ +) 20-80% syncytia, ( + + +) >80% syncytia.
Table 5. Inhibition of HIV Infection of CD4 4 Cells by CD4 mAbs
Syncytium formation RT activity Soluble p24 antigen
CD4 mAbs (5 ug/ml) 3 dt 4 d 5 d 3d 4d 5d 3d 4d 5d
cpm ng/ml
Leu-3a (1)'' _S 468 401 430 0 0 10
Q425 (3) 414 558 875 20 20 70
Q428 (3) - + + 517 1,167 3,824 15 40 290
MT429 (3,4) + + + + + + + + 856 3,095 8,219 50 240 3,000
Cells plus virus only + + + + + + + + 1,322 5,509 9,946 30 310 3,300
Cells alone - - - 397 267 300 5 0 0
Table 4. Inhibition ofHIV-induced Syncytium Formation by CD4 mAbs
HIV isolate
HIV-1 HIV-2
Saturation
CD4 mAb binding# IIIRF IIIB CBL4 LAV-2 CBL20
'Uglm1 ,uglm1
Leu-3a (1)' 0.04 0.315 0.31 <0.31 <0.31 <0.31
Q4120 (1) 0.08 <0.3 <0.3 <0.3 <0.3 <0.3
Q425 (3) 0.63 20 1.25 1.25 1.25 0.31
Q428 (3) 0.63 2.5 5.0 2.5 5.0 0.6
MT429 (3,4) 0.63 >20 >20 >20 >20 >20
L120 (4) 0.63 >20 >20 >20 >20 >20Discussion
We have demonstrated that two novel CD4 mAbs, Q425
and Q428, which bind within the third extracellular domain
of CD4, block HIV infection and cell fusion without in-
hibiting virus binding. Recent studies have shown that recom-
binant V1 binds to gp120 with an affinity similar to that of
whole sCD4 (6) . Hence, mAbs reactive with the first or first
and second domains of CD4 directly inhibit gp120 binding
and efficiently block HIV infection and cell fusion, whereas
a mAb bound more to a membrane proximal region has been
shown not to affect HIV binding or syncytium formation
(18, 19). Since HIV is thought to enter cells by direct fusion
of the virus with the cell plasma membrane without inter-
nalization ofCD4 (32, 33), mAbs Q425 and Q428 probably
interfere with a step aftervirus binding but before virus entry.
The finding that Q425 and Q428 inhibit cell-cell fusion in
an overnight cocultivation assay in which virus infection and
replication are not required supports the concept that the block
to infection is before membrane fusion. The substitution of
the third and fourth domains of CD4 for the hinge, trans-
membrane, and cytoplasmic segments of CD8 results in a
chimeric molecule, which when expressed in a CD4- cell
line, confers susceptibility to HIV infection (32). Thus, con-
servation of the region of CD4 to which Q425 and Q428
binds is not required to allow HIV entry into receptor-bearing
cells. This implies that the epitopes recognized by these mAbs
are not involved in binding a ligand such as a second receptor
molecule. The observed inhibition of HIV infection and cell
fusion by these mAbs may be explained by the following
model. Like some other members of the Ig superfamily (34,
35), CD4 may have a hinge-like region. A study supporting
this based on crystallization of sCD4 predicts a hinge be-
tween domains 2 and 3 (36). Since CD4 is an extended rod-
like molecule of -125 A in length (36), and fusion of two
membranes probably requires greater proximity than this (37),
bending of a hinge may be necessary for fusion to take place.
The binding of Q425 or Q428 may restrict such movement.
The portion ofCD8 replacing domains 3 and 4 ofCD4, de-
scribed above (32), might substitute functionally in allowing
flexibility, rendering this molecule permissive for HIV fu-
sion with the cell membrane. An observation potentially rele-
vant to the idea of a hinge is the reduced binding of Q425
and Q428 to CD4 in the presence of gp120. Since binding
of the other third- or fourth-domain mAbs is not affected
by gp120, and V1-reactive CD4 mAbs do not mimic gp120
and inhibit Q425 and Q428 binding, the Q425 and Q428
epitopes are uniquely sensitive to bound gp120. The lack of
reciprocal inhibition suggests that gp120 may impose a con-
formational change in CD4, such as bending of the hinge,
reducing the affinity of Q425 and Q428 for this region.
An alternative explanation for the inhibition of fusion by
Q425 and Q428 is that their binding to CD4 prevents
virus-cell or cell-cell membrane fusion by steric interference
with the fusogenic apparatus of HIV gp41. At present, we
have no way of discriminating between these two hypotheses.
Two recent studies address the possibility that HIV envelope-
mediated fusion of CD4-containing membranes may require
CD4 activity additional to gp120 binding. Mutations in the
CDR-3 analogous region of the V1 domain of CD4 did not
disrupt gp120 or HIV binding, but did abrogate syncytium
formation (14). Interestingly, cells expressing the mutant forms
of CD4 were as susceptible to infection by cell-free virus as
those containingwild-type CD4. Thus, a region in the first
domain of CD4 adjacent to the gp120 high affinity binding
site may have a role in cell-cell fusion. Since the epitopes of
mAbs Q425 and Q428 are distant from the CD4/V1 do-
main, and these mAbs block both HIV infection and cell
fusion, it seemslikely that these two studies described different
mechanisms.
In another study, chemical mutagenesis of CD4+ T cells
was used to isolate variant CD4 phenotypes (15). Two ofthese
variants had a decreased ability to form syncytia with envelope-
expressing cells, but bound gp120 with a similar avidity to
wild-type CD4+ cells. Although these authors did not at-
tempt infection studies with cell-free virus, and the CD4 vari-
ants have not been characterized, it seems possible that mu-
tations between the second and third domains of CD4 may
account for the observed results.
We show here that in addition to binding HIV to the cell
surface, CD4 may participate in both virus fusion with the
cell membrane, an event critical for infection, and HIV
envelope-mediated syncytium formation, a potential mecha-
nism for virus spread and cytopathology. This finding may
have relevance not only to mechanisms ofHIVmediated mem-
branefusion, but may also increase our understanding ofthe
receptor-mediated entry of other enveloped viruses.
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